New insights regarding pharmacologic approaches for ovarian cancer prevention

Hematology/Oncology Clinics of North America

Volumn 17, Issue 4, 2003, Pages 1007-1020

  Rodriguez, Gustavo ^a,b,c  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FENRETINIDE; GESTAGEN; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; RETINOID; VITAMIN D;

APOPTOSIS; CALCIUM HOMEOSTASIS; CANCER RISK; CANCER SUSCEPTIBILITY; EPITHELIUM CELL; FEMALE; HUMAN; HYPERCALCEMIA; OVARY CANCER; OVULATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0042433449     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00060-1     Document Type: Review

References (82)

1. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139(7):654-61.
2. Stanford JL, Thomas DB, Ray RM, et al. Epithelial ovarian cancer and combined oral contraceptives: the WHO collaborative study of neoplasia and steroid contraceptives. Int J Epidemiol 1989;18(3):538-45.
3. Lee NC, Wingo PA, Gwynn ML, et al. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-5.
4. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83(3):419-24.
5. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer: III. oral contraceptive use. Int J Cancer 1991;49:61-5.
6. Wu ML, Whittemore AS, Paffenbarger Jr RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol 1987;28(6):1216-27.
7. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984;2(3):209-25.
8. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Invest 1998;5:271-6.
9. Canman CE, Chen C-Y, Lee MH, Castan MB. DNA damage responses p53 induction, cell cycle pertubations, and apoptosis. Cold Spring Harbor Symposia on Quantitative Biology 1994;49:277-86.
10. Chan LN, Zhang S, Cloyd M, et al. N-(4-hydroxyphenyl) retinamide prevents development of T-lymphomas in AKR/J mice. Anticancer Res 1997;17:499-503.
11. Ponzoni K, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenyl) refinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55(4):853-61.
12. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53(24):603-41.
13. Seewaldt VL, Yim JR, Caldwell LE, Johnson BS, Swisshelm Y, Collins SJ. AU-trans-retinoic acid mediates GI arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 1995;6(7):863-9.
14. Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996;10(9):1031-9.
15. Sankaranarayanan R, Mathew B. Retinoids as cancer-preventive agents. IARC Sci Publ 1996;139:47-59.
16. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, et al. Effects of - all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 1997;70(5):619-27.
17. Oridate N, Lotan D, Mitchell NW, Hong WY, Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. J Cell Biochem 1995;23(Suppl):80-6.
18. Dolivet V, Ton Van J, Sarini J, Wattel E, Lagarde P, Chomy F, et al. [Current knowledge on the action of retinoids in carcinoma of the head and neck.]. Rev Laryngol Otol Rhinol (Bord) 1996;17(1):19-26.
19. Kuo SM. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 1996;110(1-2):41-8.
20. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57(2):267-71.
21. Reddy BS, Wang CY, Samaha H, Lubet R, Steele VE, KeHoff GJ, et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997;57(3):420-5.
22. Gould MN. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 1997;105(Suppl 4):977-9.
23. Pascale M, Simile NM, De Nfigho N, Nufris A, Daino L, Seddaiu NA, et al. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promosted by orotic acid. Carcinogenesis 1995;16(2):427-30.
24. Thompson HJ, Wilson A, Lu J, Singh M, Jiang C, Upadhyaya P, et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 1994;15(2):183-6.
25. el-Bayoumy K, Upadhyaya P, Chae YH, Sohn OS, Rao CV, Fiala E, et al. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem 1995;22(Suppl):92-100.
26. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60.
27. Reiss M. Transforming growth factor-beta and cancer: A love-hate relationship? Oncol Res 1997;9:447-57.
28. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
29. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
30. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999;13:99-106.
31. De Palo G, Veronesi U, Camerini T, et al. Can fenretinide protect women against ovarian cancer. J Natl Cancer Inst 1995;87(2):146-7.
32. Campbell MJ, Park S, Uskokovic MR, et al. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analogue. Endocrinology 1998;139:1972-80.
33. Studzinski GP, Moore DC. Sunlight: can it prevent as well as cause cancer? Cancer Res 1995;55:4012-22.
34. Lefkowitz EC, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994;23(6):1133-6.
35. Koshizuka K, Kubota T, Said J, et al. Combination therapy of a vitamin D3 analogue and all-trans-retinoic acid: effect on human breast cancer in nude mice. Anticancer Res 1999;19:519-24.
36. James SY, Mercer E, Brady M, et al. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 1998;125:953-62.
37. 5. J Natl Cancer Inst 1997;89:212-8.
38. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998;351(9096):104-7.
39. Moyisch KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:903-6.
40. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933-7.
41. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2001;11:1171-3.
42. Akhmendkhanov AA, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and risk of epithelial cancer. Prev Med 2001;33:682-7.
43. Goodwin JS. Prostaglandins and host defense in cancer. Med Clin North Am 1981;65:829-44.
44. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev Med 1995;24:103-6.
45. Rodriguez-Burford C, Barnes MN, Oelschlager DK, Myers RB, Talley LI, Partridge EE, et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2001;8:202-9.
46. Wilson JE. Adeno-carcinomata in hens kept in a constant environment. Poult Sci 1958;37:1253.
47. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51.
48. Lingeman CH. Etiology of cancer of the human ovary: a review. J Natl Cancer Inst 1974;53:1603-18.
49. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-89.
50. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984;44:5286-90.
51. Nishida T, Sugiyama I, Katabuchi H, Yakushiji M, Kato T. Histologic origin of rat ovarian cancer induced by direct application of 7,12-dimethylbenz(A)anthracene. Acta Obstet Gynaecol Jpn 1986;38(4):570-4.
52. Massazza G, Tomasoni A, Lucchini V, Allavena P, Erba E, Colombo N, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989;44:494-500.
53. Fjeld JG, Vergote I, De Vos L, Nustad K. Radio-immunotargeting in experimental animal models of intraperitoneal cancer. Acta Obstet Gynecol Scand 1992;71(Suppl 155):105-11.
54. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 1993;13:283-6.
55. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AD, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994;54:2778-84.
56. Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 1996;175:593-9.
57. Molpus KL, Koelliker D, Atkins L, Kato DT, Buczek-Thomas J, Fuller AF, et al. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer 1996;67:588-95.
58. Silva EG, Tomos C, Fritsche HA, El-Naggar A, Gray K, Ordonez NG, et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10(9):879-83.
59. Yoshida Y, Kamitani N, Sasaki H, Kusumi K, Tominaga T, Kotsuhi F. Establishment of a liver metastatic model of human ovarian cancer. Anticancer Res 1998;18:327-32.
60. Silva EG, Tomos C, Deavers M, Kaisman K, Gray K, Gershenson D. Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation. Gynecol Oncol 1998;71:240-6.
61. Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, Saga M, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis 1998;16:751-6.
62. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol 1999;72:161-70.
63. Etches RJ, Petitte JN. Reptilian and avian follicular hierarchies: models for the study of ovarian development. J Exp Zoo Suppl 1990;4:112-22.
64. Woolveridge L, Peddie MJ. The inhibition of androstenedione production in mature thecal cells from the ovary of the domestic hen (Gallus domesticus): evidence for the involvement of progestins. Steroids 1997;62:214-20.
65. Dunn IC, Sharp PJ. The effect of photoperiodic history on egg laying in dwarf broiler hens. Poult Sci 1992;71:2090-8.
66. Johnson AJ, Bridgham JT, Witty JP, Tilly JL. Expression of bcl-2 and nr-13 in hen ovarian follicles during development. Biol Repro 1997;57:1097-103.
67. Eguchi Y, Ewert DL, Tsujimoto Y. Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo. Nucleic Acids Res 1992;20(16):4187-92.
68. Mayr B, Schaffner G, Kurzbauer R, Reiginger K, Schellander K. Sequence of an exon of tumor suppressor p53 gene - a comparative study in domestic animals: mutation in a feline comparative study in domestic animals: mutation in a feline solid mammary carcinoma. Br Vet J 1995;151(3):325-9.
69. Rampalli AM, Zelenka PS. Insulin regulates expression of c-fos and c-jun and suppresses apoptosis of lens epithelial cells. Cell Growth Differ 1995;6(8):945-53.
70. Qin S, Inazu T, Takata M, Kurosaki T, Homma Y, Yamamura H. Cooperation of tyrosine kinases p72syk and p53/56lyn regulates calcium mobilization in chicken B cell oxidant stress signaling. Eur J Biochem 1996;236(2):443-9.
71. Evans DL, Mansel RE. Molecular evolution and secondary structural conservation in the B-ceH lymphoma leukemia 2 (bcl-2) family of proto-oncogene products. J Mol Evol 1995;41(6):775-83.
72. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Myashita T, Hovey 3rd LR, et al. Evolutionary conservation of function among mammalian avian, and viral homologs of the bcl-2 oncoprotein. DNA Cell Biol 1994;13(7):679-92.
73. Vilgrasa X, Mezquita C, Mezquita J. Differential expression of bcl-2 and bcl-x during chicken spermatogenesis. Mol Reprod Dev 1997;47(1):26-9.
74. Bai W, Rowan BG, Allgood VE, O'Malley BW, Weigel NL. Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation. J Biol Chem 1997;272(16):10457-63.
75. Allgood VE, Zhang Y, O'Malley BW, Weigel NL. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high-efficiency DNA transfer. Biochemistry 1997;36(1):224-32.
76. Syvala I-L, Vienonen A, Ylikomi T, Blauer K, Zhuang YK, Tuohimaa P. Expression of the chicken progesterone receptor forms A and B is differentially regulated by estrogen in vivo. Biochem Biophys Res Commun 1997;231:573-6.
77. Rodriguez GC, Carver D, Anderson K, Barnes J, Berchuck A, Whitaker R, et al. Evaluation of ovarian cancer preventive agents in the chicken. Gynecol Oncol 2001;80:317.
78. Barnes MN, Berry WD, Straughn JM, Kirby TO, Leath CA, Huh WK, et al. A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecologic Oncology 2002;87(1):57-63.
79. Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M. Regulation of transforming growth factor-beta subtypes by members of the streroid hormone superfamily. J Cell Sci 1990;13(Suppl):139-48.
80. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999;13:99-106.
81. Guzey M, Sattler C, DeLuca HF. Combinational effects of vitamin D and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun 1998;249:735-44.
82. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999;283:1317-21.